R G Strauss1, L F Burmeister, K Johnson, G Cress, D Cordle. 1. Departments of Pediatrics, Preventive Medicine and Environmental Health, and Pathology, The University of Iowa College of Medicine, Iowa City, IA 52242-1182, USA.
Abstract
OBJECTIVES: Most extremely low birth weight (<1 kg) infants receive red blood cell (RBC) transfusions. RBCs stored up to 42 days can be transfused safely in small volumes to preterm infants; however, because the formulation of RBC anticoagulant/preservative solutions differs, clinical studies are required to document the safety of each solution before widespread use. Our goal was to study the feasibility and safety of AS-3 anticoagulant/preservative solution to preterm infants. STUDY DESIGN: Two clinical studies were conducted in sequence: (1) a randomized trial to compare RBC transfusions given as stored (< or =42 days) AS-3 RBCs (11 infants) versus fresh (< or = 7 days) citrate, phosphate, dextrose, and adenine RBCs (10 infants) and (2) a subsequent evaluation of the safety of stored AS-3 RBCs in 33 additional preterm infants given 120 AS-3 RBC transfusions. RESULTS: Results of both the randomized study and the subsequent evaluation documented that AS-3 RBCs stored < or =42 days and transfused in small volumes (15 mL/kg) were safe for RBC transfusions of preterm infants. Donor exposure was significantly reduced, clinical transfusion reactions were rare, and post-transfusion blood hematocrit, pH, and plasma Na, K, Ca, lactate, and glucose measurements were similar when AS-3 and citrate, phosphate, dextrose, and adenine RBC transfusions were compared. CONCLUSIONS:AS-3 RBCs can be used safely for small-volume RBC transfusions for preterm infants.
RCT Entities:
OBJECTIVES: Most extremely low birth weight (<1 kg) infants receive red blood cell (RBC) transfusions. RBCs stored up to 42 days can be transfused safely in small volumes to preterm infants; however, because the formulation of RBC anticoagulant/preservative solutions differs, clinical studies are required to document the safety of each solution before widespread use. Our goal was to study the feasibility and safety of AS-3 anticoagulant/preservative solution to preterm infants. STUDY DESIGN: Two clinical studies were conducted in sequence: (1) a randomized trial to compare RBC transfusions given as stored (< or =42 days) AS-3 RBCs (11 infants) versus fresh (< or = 7 days) citrate, phosphate, dextrose, and adenine RBCs (10 infants) and (2) a subsequent evaluation of the safety of stored AS-3 RBCs in 33 additional preterm infants given 120 AS-3 RBC transfusions. RESULTS: Results of both the randomized study and the subsequent evaluation documented that AS-3 RBCs stored < or =42 days and transfused in small volumes (15 mL/kg) were safe for RBC transfusions of preterm infants. Donor exposure was significantly reduced, clinical transfusion reactions were rare, and post-transfusion blood hematocrit, pH, and plasma Na, K, Ca, lactate, and glucose measurements were similar when AS-3 and citrate, phosphate, dextrose, and adenine RBC transfusions were compared. CONCLUSIONS:AS-3 RBCs can be used safely for small-volume RBC transfusions for preterm infants.
Authors: Jennifer Muszynski; Jyotsna Nateri; Kathleen Nicol; Kristin Greathouse; Lisa Hanson; Mark Hall Journal: Transfusion Date: 2011-10-07 Impact factor: 3.157
Authors: Ronald G Strauss; Donald M Mock; John A Widness; Karen Johnson; Gretchen Cress; Robert L Schmidt Journal: Transfusion Date: 2004-06 Impact factor: 3.157
Authors: Leonard I Boral; Zane G Staubach; Reny de Leeuw; Duncan C Macivor; Richard Kryscio; Henrietta S Bada Journal: Am J Clin Pathol Date: 2013-12 Impact factor: 2.493